Pfizer Sees No “Strategic Reason” To Keep OTC Unit, McKinnell Says
This article was originally published in The Pink Sheet Daily
Firm still weighing options for consumer unit, sees bid covering capital gains tax as “attractive” alternative to spinning off division, according to CEO.
You may also be interested in...
Johnson & Johnson CEO William Weldon says the deal will make the firm's portfolio "more balanced," with 40% devoted to pharmaceuticals, 35% to medical devices and 25% to consumer products.
The global scope of food safety is becoming apparent, and recent problems with products imported from China are but a part of U.S. food safety concerns, industry experts say